Cite
HARVARD Citation
Chen, T. et al. (2021). Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer. Journal of the Chinese Medical Association. 84 (4), pp. 361-367. [Online].